MANP in Hypertension With Metabolic Syndrome Proof-of-Concept Study of Natriuretic Peptide-Based Therapy for Cardiometabolic Disease

Hypertension and metabolic syndrome frequently coexist to increase the risk for adverse cardiometabolic outcomes. To date, no drug has been proven to be effective in treating hypertension with metabolic syndrome. M -atrial natriuretic peptide is a novel atrial natriuretic peptide analog that activates the particulate guanylyl cyclase A receptor. This study conducted a double-blind, placebo -controlled trial in 22 patients and demonstrated that a single subcutaneous injection of M -atrial natriuretic peptide was safe, well -tolerated, and exerted pleiotropic properties including blood pressure-lowering, lipolytic, and insulin resistance-improving effects. (MANP in Hypertension and Metabolic Syndrome [MANP-HTN-MS]; NCT03781739) (J Am Coll Cardiol Basic Trans Science 2024;9:18-29) (c) 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY -NC -ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).